Sopharma AD-Sofia (XBUL:SFA) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 01, 2026)


XBUL:SFA Sopharma AD-Sofia XBUL:SFA
59 GF Score
Price €1.93
GF Value €3.16
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Sopharma AD-Sofia's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XBUL:SFA vs MCK, CAH, COR: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Distribution subindustry, Sopharma AD-Sofia's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sopharma AD-Sofia Margin of Safety % (DCF Earnings Based) vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's Margin of Safety % (DCF Earnings Based) falls into.


XBUL:SFA
59GF Score
Sopharma AD-Sofia XBUL:SFA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sopharma AD-Sofia (XBUL:SFA) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of €1.93 is trading 38.9% below its estimated GF Value™ of €3.16. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for XBUL:SFA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €3.16 vs. price of €1.93 (38.9% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the XBUL:SFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges SPH:Poland3JR:Germany
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
59GF Score

Get the complete analysis for XBUL:SFA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.93
Price
€3.16
GF Value